Convection-enhanced delivery of therapeutic agents into the brain

Handbook of Clinical Neurology

Volumn 104, Issue , 2012, Pages 355-362

  Vogelbaum, Michael A ^a   Iannotti, Christopher A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855546609     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52138-5.00023-2     Document Type: Chapter

References (32)

1. Bobo R.H., Laske D.W., Akbasak A., et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994, 91:2076-2780.
2. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995, 345:1008-1012.
3. Chen M.Y., Lonser R.R., Morrison P.F., et al. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 1999, 90:315-320.
4. Degen J.W., Walbridge S., Vortmeyer A.O., et al. Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats. J Neurosurg 2003, 99:893-898.
5. Garland L., Gitlitz B., Ebbinghaus S., et al. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother 2005, 28:376-381.
6. Groothuis D.R., Ward S., Itskovich A.C., et al. Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion. J Neurosurg 1999, 90:321-331.
7. Hadaczek P., Kohutnicka M., Krauze M.T., et al. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther 2006, 17:291-302.
8. Hall W.A., Sherr G.T. Convection enhanced delivery: targeted toxin treatment of malignant glioma. Neurosurg Focus 2006, 20:E10.
9. Husain S.R., Puri R.K. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 2003, 65:37-48.
10. Kaiser M.G., Parsa A.T., Fine R.L., et al. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 2000, 47:1391-1398.
11. Kawakami K., Kioi M., Liu Q., et al. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy. J Immunother 2005, 28:193-202.
12. Kunwar S., Chang S.M., Prados M.D., et al. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus 2006, 20:E15.
13. Laccabue D., Tortoreto M., Veneroni S., et al. A novel taxane active against an orthotopically growing human glioma xenograft. Cancer 2001, 92:3085-3092.
14. Laske D.W., Youle R.J., Oldfield E.H. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997, 3:1362-1368.
15. Lidar Z., Mardor Y., Jonas T., et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 2004, 100:472-479.
16. Lonser R.R., Walbridge S., Garmestani K., et al. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. J Neurosurg 2002, 97:905-913.
17. Nguyen T.T., Pannu Y.S., Sung C., et al. Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging. J Neurosurg 2003, 98:584-590.
18. Occhiogrosso G., Edgar M.A., Sandberg D.I., et al. Prolonged convection-enhanced delivery into the rat brainstem. Neurosurgery 2003, 52:388-393.
19. Pastan I., Chaudhary V., FitzGerald D.J. Recombinant toxins as novel therapeutic agents. Annu Rev Biochem 1992, 61:331-354.
20. Puri R.K., Leland P., Kreitman R.J., et al. Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein. Int J Cancer 1994, 58:574-581.
21. Puri R.K., Hoon D.S., Leland P., et al. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Cancer Res 1996, 56:5631-5637.
22. Rand R.W., Kreitman R.J., Patronas N., et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 2000, 6:2157-2165.
23. Saito R., Krauze M.T., Noble C.O., et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro-oncol 2006, 8:205-214.
24. Sampson J.H., Akabani G., Archer G.E., et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 2003, 65:27-35.
25. Sampson J.H., Brady M.L., Petry N.A., et al. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 2007, 60:ONS89-ONS98.
26. Sanftner L.M., Sommer J.M., Suzuki B.M., et al. AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters. Exp Neurol 2005, 194:476-483.
27. Schmidt F., Schuster M., Streffer J., et al. Topotecan-based combination chemotherapy for human malignant glioma. Anticancer Res 1999, 19:1217-1221.
28. Shimamura T., Husain S.R., Puri R.K. IL-4 and IL-13 pseudomonas exotoxins: new hopes for brain tumor therapy. Neurosurg Focus 2006, 20:E11.
29. Vogelbaum M.A. Convection enhanced delivery for the treatment of malignant gliomas: symposium review. J Neurooncol 2005, 73:57-69.
30. Weaver M., Laske D.W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003, 65:3-13.
31. Weber F., Asher A., Bucholz R., et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol 2003, 64:125-137.
32. Wong A.J., Bigner S.H., Bigner D.D., et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 1987, 84:6899-6903.